Jaihind Industries Limited has scheduled a meeting of its Board of Directors for Thursday, May 28, 2026. The primary agenda for the meeting is to consider and approve the audited financial results of the company for the fourth quarter and the financial year ended March 31, 2026.

This intimation is being issued in compliance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will review the performance of the company for the specified period before finalizing the statements.

In accordance with the company’s Insider Trading Policy and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window has been closed. The window shall remain closed until 48 hours after the publication of the audited financial results.

Meeting Details

The company has requested the stock exchange to take the intimation on record and acknowledge receipt. Jaihind Industries Limited was formerly known as Jaihind Synthetics Ltd.

Jaihind Industries Limited has incorporated a wholly-owned subsidiary named Wellness & Medicinal Oasisz Private Limited with a 78% shareholding. The subsidiary was registered with the Registrar of Companies on May 13, 2026, as per a Certificate of Incorporation. The company disclosed this information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The newly incorporated entity operates in the healthcare and pharmaceutical industry. As it is a recently established company, it has not yet commenced business operations, and its turnover is currently nil. The registered office of Wellness & Medicinal Oasisz Private Limited is located in Mumbai, India.

Financial Details of the Subsidiary

The financial structure of the subsidiary includes an authorized and paid-up capital of ₹1,00,000. This capital is divided into 10,000 equity shares with a face value of ₹10 each. The cost of acquisition for the 78% stake was ₹78,000, which was paid through cash consideration.

Strategic Objectives

The incorporation of this subsidiary aligns with Jaihind Industries' strategy to expand its footprint in the healthcare and pharmaceutical sectors. The company aims to explore opportunities in hospital infrastructure, medical services, wellness, healthcare management, and allied activities through this new venture. Management expects this move to strengthen its long-term business portfolio and create growth opportunities within the healthcare industry.

The transaction does not fall under related party transactions, and no specific governmental or regulatory approvals were required for the acquisition. The promoter and promoter group have no interest in the transaction other than what has been disclosed.